Clinical Trials Directory

Trials / Completed

CompletedNCT00004354

Study of Prevalence and Clinical Phenotype in Patients With Glucocorticoid-Remediable Aldosteronism

Status
Completed
Phase
Study type
Observational
Enrollment
Sponsor
National Center for Research Resources (NCRR) · NIH
Sex
All
Age
0 Years
Healthy volunteers
Not accepted

Summary

OBJECTIVES: I. Determine the prevalence of glucocorticoid-remediable aldosteronism (GRA) in various hypertensive populations and screen at risk members of GRA pedigrees. II. Investigate other factors regulating blood pressure in GRA (environmental, genetically determined factors). III. Investigate renal and hormonal mechanisms regulating potassium homeostasis in GRA. IV. Describe clinical phenotype of GRA patients. V. Prospectively screen GRA-affected patients with MRI angiography for intracranial aneurysm.

Detailed description

PROTOCOL OUTLINE: Patients are screened for high blood pressure, suppressed plasma renin activity level, and low potassium levels. Urine is collected for a 24 hour period. Blood specimen is collected for molecular biologic evaluation for the presence of the chimeric gene diagnostic of GRA. Any history of cardiovascular events is recorded.

Conditions

Timeline

Start date
1999-06-01
First posted
1999-10-19
Last updated
2005-06-24

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00004354. Inclusion in this directory is not an endorsement.

Study of Prevalence and Clinical Phenotype in Patients With Glucocorticoid-Remediable Aldosteronism (NCT00004354) · Clinical Trials Directory